Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Tampa, Florida Clinical Trials

A listing of Tampa, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (32) clinical trials

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in patients with prostate cancer and cardiovascular disease.

Phase

0.51 miles

Learn More »

Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)

This clinical trial is designed as a randomized, placebo-controlled, multi-center phase 2 trial to evaluate the efficacy and safety of OPK-88004 in men with benign prostatic hyperplasia. Eligible subjects will be randomized into one of two OPK-88004 treatment groups or a placebo group after a 4-week screening period. Subjects will ...

Phase

0.51 miles

Learn More »

Multi-Institutional Registry for Prostate Cancer Radiosurgery

To address pertinent questions regarding the utilization of radiosurgery (SBRT) to treat prostate cancer. The Florida Robotic Radiosurgery Association (FRRA) launched the first registry for prostate cancer patients treated with SBRT. The registry is designed to track surrogate treatment endpoints including PSA, IPSS, SHIM, QOL, Karnofsky Performance Status, VAS scores, ...

Phase N/A

0.83 miles

Learn More »

A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX ) in Patients With Prostate Cancer

This will be a randomized, open-label and active-control study to assess the PK, PD and safety profiles of LY01005 versus goserelin comparator to be conducted in the USA.

Phase

0.83 miles

Learn More »

Meridien Research needs volunteers for a new clinical trial of a BPH medication that treats night time urination (nocturia). Call Meridien Research today at 813-877-8839 to see if you qualify!

Phase N/A

1.75 miles

Learn More »

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

The purpose of this study is to determine the frequency of bleeding episodes in patients receiving fitusiran as prophylactic treatment of hemophilia compared with patients who are assigned to continue with their regular medication. In addition, the study will assess safety, quality of life, pharmacodynamics (PD), and pharmacokinetics (PK).

Phase

5.77 miles

Learn More »

Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.

This trial is conducted globally. The aim of this trial is to evaluate the haemostatic effect of NNC 0129-0000-1003 during surgical procedures in subjects with haemophilia A.

Phase

6.1 miles

Learn More »

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

The purpose of this study is to determine the frequency of bleeding episodes in patients receiving fitusiran as prophylactic treatment of hemophilia compared with patients who are assigned to continue with their regular medication. In addition, the study will assess safety, quality of life, pharmacodynamics (PD), and pharmacokinetics (PK).

Phase

6.1 miles

Learn More »

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

Primary Objective: The primary safety objective is to assess the effects of arbaclofen ER tablets (AERT) compared with placebo on sperm concentration from baseline to the end of 90 days of treatment in male subjects with MS. Secondary Objectives: The secondary safety objectives are to assess: - The effects of ...

Phase

7.72 miles

Learn More »

Study of RG-012 in Male Subjects With Alport Syndrome

This is a randomized, double-blind, placebo-controlled, multi-center, Phase 2 study of RG-012 in male subjects with Alport syndrome. Eligible subjects will be randomized in a 1:1 ratio to receive subcutaneous (SC) injections of RG-012 or placebo every other week for 48 weeks. After completion of this double-blind treatment period, subjects ...

Phase

7.72 miles

Learn More »